The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

Podobne zapisy

• Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
  od: Balayan, Tatevik, i wsp.
  Wydane: (2017)
• Unemployment, health, and education of HIV-infected males in Germany
  od: Groß, Mona, i wsp.
  Wydane: (2015)
• Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines
  od: Treskova, Marina, i wsp.
  Wydane: (2016)
• Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings
  od: Lima, Viviane D, i wsp.
  Wydane: (2016)
• Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
  od: Alexandra U Scherrer, i wsp.
  Wydane: (2012-01-01)